spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  aztreonam 

 HSMN NewsFeed - 11 Nov 2019
Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jun 2016
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2016
Allergan Announces Collaboration with AstraZeneca to Develop and Commercialize ATM-AVI (aztreonam and avibactam) for Antibiotic-Resistant Gram-Negative Infections
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 29 Nov 2012
Rib-X Pharmaceuticals Closes First Tranche in $67.5 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Oct 2010
Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2010
APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Mar 2009
European CHMP Adopts Negative Opinion on Aztreonam Lysine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Feb 2009
Gilead Receives Response From U.S. FDA on Company's Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 6 Jan 2009
Horizon Therapeutics Announces Senior Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2008
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 7 Mar 2008
Gilead Sciences Submits Marketing Authorisation Application for Aztreonam Lysine 75 mg Powder for Nebuliser Solution, a Potential New Treatment for Cystic Fibrosis, to European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
Gilead Announces Detailed Results of Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2007
Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 19 Apr 2007
Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals Devices
 HSMN NewsFeed - 19 Dec 2006
Gilead Announces Preliminary Results From Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
aztreonam
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.